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OBJECTIVES We compared the effects of five pharmacologic regimens on the circadian rhythm and
exercise-induced changes of ventricular rate (VR) in patients with chronic atrial fibrillation
(CAF).
BACKGROUND Systematic comparison of standardized drug regimens on 24 h VR control in CAF have not
been reported.
METHODS In 12 patients (11 male, 69 6 6 yr) with CAF, the effects on VR by 5 standardized daily
regimens: 1) 0.25 mg digoxin, 2) 240 mg diltiazem-CD, 3) 50 mg atenolol, 4) 0.25 mg
digoxin 1 240 mg diltiazem-CD, and 5) 0.25 mg digoxin 1 50 mg atenolol; were studied
after 2 week treatment assigned in random order. The VR data were analyzed by ANOVA
with repeated measures. The circadian phase differences were evaluated by cosinor analysis.
RESULTS The 24-h mean (6SD) values of VR (bpm) were 2 digoxin: 78.9 6 16.3, diltiazem: 80.0 6
15.5, atenolol: 75.9 6 11.7, digoxin 1 diltiazem: 67.3 6 14.1 and digoxin 1 atenolol: 65.0 6
9.4. Circadian patterns were significant in each treatment group (p , 0.001). The VR on
digoxin 1 atenolol was significantly lower than that on digoxin (p , 0.0001), diltiazem (p ,
0.0002) and atenolol (p , 0.001). The time of peak VR on Holter was significantly delayed
with regimens 3 and 5 which included atenolol (p , 0.03). During exercise, digoxin and
digoxin 1 atenolol treatments resulted in the highest and lowest mean VR respectively. The
exercise Time-VR plots of all groups were nearly parallel (p 5 ns). The exercise duration was
similar in all treatment groups (p 5 ns).
CONCLUSIONS This study indicates that digoxin and diltiazem, as single agents at the doses tested, are least
effective for controlling ventricular rate in atrial fibrillation during daily activity. Digoxin 1
atenolol produced the most effective rate control reflecting a synergistic effect on the AV
node. The data provides a basis for testing the effects of chronic suppression of diurnal
fluctuations of VR on left atrial and ventricular function in CAF. (J Am Coll Cardiol 1999;
33:304–10) © 1999 by the American College of Cardiology
Atrial fibrillation has recently emerged as the most common
cardiac arrhythmia in clinical practice (1). It is now recog-
nized as being responsible for significant morbidity and
increased mortality (2). It has been known that with the
onset of atrial fibrillation the mean ventricular rate over 24 h
is substantially higher than that during sinus rhythm in the
same patient during atrial fibrillation. Such an increase in
heart rate may lead to a complex of adverse reactions
including palpitations, dizziness, lassitude, shortness of
breath and symptoms of heart failure in patients with
significant heart disease (3). Sustained increases in ventric-
ular rate (VR) during atrial fibrillation lead to decrease in
left ventricular ejection fraction (LVEF) to a variable degree
(4). To this must be added the significant incidence of
thromboembolic stroke (5). There is evidence suggesting
that the overall complex of adverse reactions can be reduced
by restoration and maintenance of sinus rhythm (6) or VR
control by AV conduction blocking drugs combined with
anticoagulants (7). However, the relative superiority of these
two approaches in the treatment of atrial fibrillation is
uncertain, but it is the subject of several major ongoing
clinical trials.
Therefore, control of the ventricular response combined
with anticoagulation remains one of the two primary goals
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in the treatment of chronic atrial fibrillation (CAF) that is
widely used in clinical practice. Historically, digitalis has
been the pharmacologic agent of choice in control of
ventricular response in atrial fibrillation (8). However, it has
been suggested that in a fairly large group of patients the
heart rate during exercise and even during normal daily
activity cannot be adequately controlled with digitalis alone
(9–13). Other agents including beta-adrenergic blocking
agents and rate-lowering calcium-channel blockers alone
and in combination with digoxin have been investigated and
found to be more effective in reducing ventricular response
in these patients (9–11,14–21). Beta-blockers are effective
in reducing the VR in CAF at rest and during exercise (22).
Verapamil and diltiazem, two calcium-channel blockers
with potent negative dromotropic properties, have been
studied extensively in CAF, and have been found to produce
strikingly similar effects on VR control (18). When com-
bined with digoxin, these agents commonly produce VR
reductions that are more pronounced at rest and during
exercise (18,20,21,23,24). However, the rate control over
24 h by the standard drug regimens has not been system-
atically investigated (25). The purpose of this study was to
compare the effects of 5 standard drug regimens consisting
of digoxin, diltiazem, atenolol, digoxin 1 diltiazem and
digoxin 1 atenolol on the mean 24-h heart rates, circadian
patterns of ventricular responses and on programmed exer-
cise in the same group of patients with CAF.
METHODS
Study patients. Twelve patients (11 men and 1 woman,
mean age 69 6 6 yr, range 57 to 78 yr) took part in the
study. All had documented CAF, resistent to attempted
cardioversion, of at least one year duration. All patients were
carefully evaluated by history, physical examination, ECG,
chest X-ray and echocardiography. Seven of the 12 had lone
atrial fibrillation and five had one or more underlying
cardiovascular disorders, including hypertension (n 5 5),
surgically corrected mitral stenosis (n 5 1) and ischemic
heart disease (n 5 2). Three of the 12 did not receive
beta-blocker therapy due to chronic obstructive pulmonary
disease. All patients were in New York Heart Association
functional class I or II. All antiarrhythmic drugs were
discontinued before the start of the study. Before this study,
the subjects were on digoxin for ventricular rate control.
Two patients received additional calcium channel blocker
therapy with either verapamil or diltiazem.
Exclusion criteria. The patients with echocardiographic
LVEF less than 35%, heart rate less than 55 bpm, Wolff-
Parkinson-White syndrome, clinically significant renal, thy-
roid or hepatic dysfunction, uncontrolled hypertension, sick
sinus syndrome, implanted pacemaker, unstable angina or
acute myocardial infarction or persistent systolic blood
pressure less than 95 mm Hg were excluded from the study.
Patients receiving other medications such as theophylline,
clonidine or inhaled beta-agonists, which might affect
ventricular response in AF, as well as those with previous
exposure to amiodarone, were excluded. Subjects who re-
cently used an investigational drug or those with a history of
untoward reaction to any of the medications used in the
present study were also excluded.
All patients gave informed consent before participation in
the study. The protocol was approved by the Human
Investigations Committee at this institution.
Study design. In a crossover, open-label outpatient study,
the following five treatment regimens were investigated: 1)
digoxin 0.25 mg/day, 2) diltiazem-CD 240 mg/day, 3)
atenolol 50 mg/day, 4) digoxin 0.25 mg/day plus
diltiazem-CD 240 mg/day and 5) digoxin 0.25 mg/day plus
atenolol 50 mg/day. These doses were selected for fixed
drug regimens as being those that had been reported to be
effective and best tolerated in the largest numbers of patients
with atrial fibrillation. For example, Roth et al. (23) re-
ported excessive side effects with 360 mg/day of diltiazem-
CD. Lanas et al. (26) reported that in patients with CAF,
100 mg/day atenolol was associated with deterioration of
NYHA functional class, whereas 0.25 mg/day of digoxin
was well tolerated. All medications were administered once
daily. The patients received each of the drug regimens in a
random sequence. Each regimen was administered for two
weeks, ensuring that steady-state drug concentrations were
attained and provided for an adequate period of washout of
the previous treatment regimen. Following the two-week
period on each regimen, a 24-h Holter recording was
obtained and the mean VR during each hour were calcu-
lated. All Holter tapes were analyzed on a Del Mar Strata
Scan 563 scanner (Del Mar Avionics, Irvine, California) by
a single experienced biotechnician. The Holters were re-
peated if there were less than 21 h of artifact-free recording.
All the tapes included in the analysis yielded an hourly mean
VR for each of the 24 h without missing values.
On the following morning, a symptom-limited
progressive-load treadmill exercise test was performed using
the modified Naughton protocol (6). Patients were in-
structed to abstain from food and coffee for at least 4 h
before testing. A standard 12-lead ECG and blood pressure
were obtained at rest and throughout the exercise test and
recovery period. Following the completion of the treadmill
study, patients were started on the next randomly assigned
Abbreviations and Acronyms
ANOVA 5 analysis of variance
AV node 5 atrio-ventricular node
bpm 5 beats per minute
CAF 5 chronic atrial fibrillation
LVEF 5 left ventricular ejection fraction
VR 5 ventricular rate
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treatment regimen until the entire sequence of treatment
schedules was completed.
Statistical analysis. The hourly mean VR derived from
24-h Holters were subjected to analysis of variance
(ANOVA) with repeated measures to test for the existence
of circadian patterns of VR, to evaluate the effect of
treatment on mean VR and to evaluate the effect of
treatment on the circadian patterns of VR (27). Because
each patient was crossed over to multiple therapies, the
differences in VR response among treatment groups were
adjusted by specifying the individual mean rate as a covari-
ate. Sphericity test was applied for the orthogonal compo-
nents and degrees of freedom were corrected, if necessary,
according to Huynh-Feldt statistics. To compare the effect
of different treatments on the phase of the circadian pat-
terns, the 24-h VR data of each subject were modeled by a
cosine curve (cosinor analysis) through nonlinear regression
analysis (28). The VR data during the first 5 min of exercise
(most subjects exercised for at least 5 min) was also subjected to
ANOVA with repeated measures as above with the indi-
vidual mean VR over all treatments as the covariate. The
VR data were tested for a linear trend with respect to time.
The issue of multiple comparisons among treatments was
addressed using Fisher’s protected approach, i.e., the
experiment-wise null hypothesis was rejected using a 4
degree of freedom F-test before testing specific contrasts.
Bio-Medical Data Processing (BMDP) Statistical Software
(Los Angeles, California) was used.
RESULTS
Ventricular rate control over 24 hours. Figure 1 shows
the mean circadian patterns of VR for each treatment
group. During combined treatment with digoxin and
atenolol, the mean VR was the lowest with minimal
circadian variation. ANOVA with repeated measures,
using hour of the day as the within factor and treatment
as the grouping factor, showed that the circadian patterns
were significantly different (nonparallel) among treat-
ment groups (p , 0.0001) and the differences in the
overall mean VR were also significantly different (p ,
0.0001). Each of the treatment groups showed a signif-
icant circadian pattern (p , 0.001) when analyzed
individually. For pairwise comparisons between treat-
ment groups, the statistical program tested the null
hypotheses: a) the VR is the same between the two
treatments, and b) the circadian patterns of the treatment
groups are parallel. The differences in circadian patterns
in Figure 1 seem more prominent during the day. The
comparisons of mean VR among the treatment groups are
summarized in Table 1 for the 24 h period as well as for
daytime (6 am to 6 pm) and nighttime (6 pm to 6 am). In
general, the combination drug regimens produced mark-
edly lower mean VR compared with the single drug
regimens. Although digoxin 1 diltiazem regimen had the
lowest VR during nighttime, it produced a distinct peak
during daytime (Fig. 1). In contrast, digoxin 1 atenolol-
Figure 1. Circadian distribution of hourly mean VR in patients
with CAF as influenced by various treatment regimens (Dig 1
dilt 5 digoxin 1 diltiazem; Dig 1 atn 5 digoxin 1 atenolol). The
“hour of the day” refers to a 24 h clock with hour 0 being midnight.
All regimens exhibited significant circadian variation of VR (p ,
0.001). Digoxin and diltiazem given alone had similar overall rates
during the 24 h. Compared with digoxin, atenolol alone and
digoxin 1 atenolol markedly attenuated the circadian rhythmicity.
Note that beta-blockade tended to shift the peak ventricular rate to
a later time in the afternoon and the combination of digoxin and
atenolol was the most effective regimen in reducing the ventricular
rate in atrial fibrillation. See text for details.
Table 1. Comparisons of Mean Ventricular Rates (VR) Measured over 24 Hours, During
Daytime (6 am to 6 pm), and During Nighttime (6 pm to 6 am)
Treatment Group
24 Hour VR





Digoxin 78.9 6 16.3 (10) 84.7 6 19.6 72.8 6 13.5
Diltiazem 80.0 6 15.5 (12) 83.8 6 18.4 76.3 6 13.2
Atenolol 75.9 6 11.7 (8) 77.0 6 14.6 74.8 6 9.9
Digoxin 1 diltiazem 67.3 6 14.1* (12) 71.8 6 17.4‡ 62.9 6 11.2\
Digoxin 1 atenolol 65.0 6 9.4† (9) 64.7 6 10.3§ 65.4 6 9.2¶
*This value is lower than those with digoxin (p , 0.004), diltiazem (p , 0.0005) and atenolol (p , 0.007) treatments. †This
value is lower than those with digoxin (p , 0.0001), diltiazem (p , 0.0002) and atenolol (p , 0.001) treatments. ‡This value
is lower than those with digoxin (p , 0.02) and diltiazem (p , 0.007) treatments. §This value is lower than those with digoxin
(p , 0.0001), diltiazem (p , 0.0001), and atenolol (p , 0.002) and digoxin 1 diltiazem (p , 0.02) treatments. \This value is
lower than those with digoxin (p , 0.004), diltiazem (p , 0.0001) and atenolol (p , 0.0002). ¶This value is lower than those
with diltiazem (p , 0.002) and atenolol (p , 0.007).
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treated group exhibited minimum differences between
day and night (Table 1). The circadian patterns of VR of
patients on digoxin, diltiazem and digoxin 1 diltiazem
treatments were substantially parallel and were signifi-
cantly different from those on atenolol and digoxin 1
atenolol (p , 0.001).
Cosinor analysis of circadian variation. In the atenolol-
and digoxin 1 atenolol-treated groups, the midday peak
was markedly attenuated with the development of a
smaller peak later in the evening. The 24-h VR data of
each subject were fitted to a cosine curve through
nonlinear regression (28). In most cases, the single cosine
function fit seemed adequate as a first approximation.
However, 8 out of 53 recordings analyzed were excluded
from statistical comparisons because the root mean
squared deviations of the observed values from the cosine
fit exceeded the estimated amplitude of the cosine curve
(i.e., signal to noise ratio ,1). The hourly mean VR data
and the corresponding cosine curves of 4 cases represent-
ing—typical, best, borderline accepted and borderline
rejected fits—are presented in Figure 2. The excluded
cases were distributed evenly over all the treatment
groups (Table 2), suggesting that there is no treatment
bias in exclusion. The time of peak VR from midnight
was calculated from the estimated phase of the cosine fit,
and the mean values of each group are presented in Table
2. The time of peak VR was significantly prolonged (p ,
0.03) when atenolol was included in the treatment
(Groups 3 and 5 of Table 2) compared with other groups.
Ventricular rate changes during exercise. The mean VR
changes for each treatment group during 12 min of exercise are
presented in Figure 3. For the purpose of statistical analysis,
the VR changes during the first 5 min were chosen because 50
out of 53 attempted exercise tests contained complete data for
this duration. According to ANOVA with repeated measures,
the exercise curves (time vs. VR plots) showed a significant
linear trend (p , 0.0001) and were substantially parallel with
nonsignificant differences in slopes (p 5 ns). When all the
groups were analyzed together, the effect of treatment was
Figure 2. Cosinor modeling of the circadian pattern of VR in
patients with CAF for comparison of the effects of different
treatments on the phase of the circadian patterns. The 24-h VR
data of each subject were fitted to a cosine curve through a
nonlinear regression analysis. The hourly mean VR data and the
corresponding cosine curves of 4 cases representing typical, best,
borderline accepted and rejected fits are presented. The time of
peak ventricular rate from midnight was calculated from the
estimated phase of the cosine fit. See Table 2 and the text for
details.
Figure 3. Effect of various pharmacologic regimens on exercise-
induced VR in patients with CAF. There was a linear trend in
increases in VR on all 5 regimens. The mean VR on digoxin 1
atenolol treatment was the lowest and was significantly lower than
those on digoxin, diltiazem and digoxin 1 diltiazem. See text for
details.
Table 2. Comparison of Phase Angle of Cosine Fit to 24 Hour Ventricular Rate Data and












1. Digoxin 3.7 6 0.5 13.6 6 1.8 9 2
2. Diltiazem 4.0 6 0.5 14.5 6 2.4 10 2
3. Atenolol 4.8 6 0.7* 17.5 6 2.6* 8 1
4. Digoxin 1 diltiazem 3.5 6 0.8 12.6 6 2.8 10 2
5. Digoxin 1 atenolol 5.1 6 1.2* 18.5 6 4.5* 8 1
*Significantly more delayed than digoxin-, diltiazem- and dig 1 diltiazem-treated groups (p , 0.03). The time of peak
ventricular rate was significantly delayed (p , 0.03) when atenolol was included in the treatment (Groups 3 and 5).
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significant (p , 0.0001) which is reflected in the vertical
separation of the exercise curves in Figure 3. The treatment
effect was not significantly different at different VR during
exercise (p 5 ns), even when both linear and nonlinear
components in the exercise curves were considered together.
The digoxin-treated group had the highest mean VR (125 6
28 beats per minute [bpm]), which was significantly higher
than that of diltiazem (105 6 15 bpm, p , 0.02), atenolol
(93 6 26 bpm, p , 0.005), digoxin 1 diltiazem (102 6 29
bpm, p , 0.03) and digoxin 1 atenolol (82 6 9 bpm, p ,
0.0001) treatment groups. The VR on digoxin 1 atenolol
treatment was the lowest and was significantly lower than those
on digoxin (p , 0.0001), diltiazem (p , 0.0001) and
digoxin 1 diltiazem (p , 0.01). It was lower than VR on
atenolol with borderline significance (p 5 0.077).
The mean exercise parameters of subjects who exercised
for at least 5 min are presented in Table 3. The peak exercise
VR for the atenolol- and digoxin 1 atenolol-treated groups
were lower than those of the other groups and were
significantly lower than that in the digoxin treated group
(p , 0.01). The mean exercise durations were similar in all
treatment groups (p 5 ns). The peak systolic blood pressure
of the atenolol treated group was the lowest and was
significantly lower than those for all other groups except for
that on the digoxin 1 atenolol-treated group (p , 0.05).
The peak diastolic blood pressures followed a similar trend
without statistical significance.
DISCUSSION
Although many studies have compared two or three medical
regimens for the control of VR in atrial fibrillation, to our
knowledge, direct comparisons of such multiple regimens
using the same cohort of patients in a crossover design have
not been reported. Furthermore, VR control in CAF, as a
function of the time of the day, has not been compared
among different drug regimens. In the current study, it was
our goal to compare the precise degree of control of
ventricular responses achieved during daily activities and
controlled exercise on five regimens in common clinical use.
The only agent in common use that was excluded was
verapamil; its effects are virtually identical to those of
diltiazem at rest and during exercise (18) while it interacts
pharmacokinetically with digoxin (29).
Circadian rhythmicity of ventricular rate control. The
results revealed that the circadian pattern of VR changes
seen in CAF treated with digoxin was maintained at a
somewhat equal level with calcium-channel antagonism
with diltiazem. In contrast, atenolol lowered the rate
predominantly during the daytime, being less effective
when beta-adrenergic stimulation was low as during sleep
(30). Furthermore, the beta-blocker markedly attenuated
VR without abolishing its circadian pattern. The most
effective regimen for attenuating increases in the VR over
the entire 24 h as well as during exercise was the
combination of beta-blockade and digoxin, a regimen
which is known to induce a marked reduction in adren-
ergic activity with an augmentation in vagal activity. Our
data indicated that the effects of atenolol and digoxin on
modulating the VR in atrial fibrillation was synergistic
both during daily activities over 24 h as well as during
treadmill exercise. For example, linear increases in ven-
tricular response on all five regimens during treadmill
exercise were found but, again, the combination of
digoxin and atenolol was the most effective regimen in
attenuating the VR during exercise. Thus, the overall
findings of this study have much clinical significance
insofar as they allow a rational basis for the choice of
individual drugs as well as combination regimens for VR
control in CAF over the diurnal cycle as well as physical
activity. It should be emphasized that beta-blockade may
reduce exercise capacity (22), whereas calcium-channel
blockers such as verapamil or diltiazem may increase it
while controlling the ventricular response (31) in atrial
fibrillation. No such differences were found in our study
which, in contrast to previous reports, used exercise
protocol that did not produce maximal stress. However,
different doses of drugs may result in differences in
exercise parameters.
Changing role of digoxin in ventricular rate control.
Digoxin as a single regimen, although still being the most
widely used as first-line therapy for VR control in atrial
fibrillation, proved less effective in this study, both during














Digoxin 175 6 36 (11) 10.5 6 4.4 164 6 21 91 6 9
Diltiazem 151 6 27 (11) 10.8 6 4.2 163 6 19 85 6 7
Atenolol 130 6 34* (9) 10.8 6 3.7 138 6 16† 82 6 10
Digoxin 1 diltiazem 146 6 40 (11) 10.8 6 4.3 158 6 25 86 6 9
Digoxin 1 atenolol 126 6 29* (8) 11.0 6 3.6 155 6 19 88 6 7
*Significantly lower than that on digoxin treatment. †Significantly lower than that on digoxin, diltiazem and digoxin 1 diltiazem
treatments, but not on digoxin 1 atenolol.
n 5 number of subjects; BP 5 Blood Pressure.
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ordinary daily activities as well as during treadmill exercise.
However, its effects over 24 h were similar to that of a
moderate dose of diltiazem-CD given alone. Nevertheless,
during exercise, diltiazem, a calcium channel-blocker which
exhibits a significant degree of noncompetitive adrenergic
antagonism, significantly attenuated the exercise-induced
increases in VR against the background of digoxin therapy
which acts largely by its vagomimetic action on the AV
node. The combination of the inhibitory effects of digoxin
and diltiazem on the AV node seemed to be synergistic
particularly during exercise, particularly in the pattern of
control of VR over 24 h. The combination regimen pro-
vided a significantly greater VR control than individual
agents, as previously reported (23). Higher doses (e.g.,
360 mg/day) of diltiazem than that used in this study (240
mg-CD) have been found to markedly increase side effects
without significant improvement in VR control (23).
The effect of digoxin plus beta-blockade for ventricular
rate control. The most striking finding in the current study
was the effect of the combined action of atenolol and
digoxin during exercise as well as over the 24 h noted on
Holter recordings. The mean VR over the 24 h was lower
on digoxin 1 atenolol than those on all other regimens
studied reflecting the synergistic effect on the AV node of
the vagomimetic actions of the cardiac glycoside and of the
beta-blocking actions of atenolol. It is likely that a similar or
even a greater effectiveness on VR control might have
resulted from higher dose of the beta-blocker alone. How-
ever, it is known that higher doses of beta-blockers are
associated with a greater incidence of adverse reactions and
possibly diminished exercise capacity (26). On the other
hand, the shift of the peak ventricular response from about
a mean of 13 h to 18 h during the 24-h period in the case
of atenolol suggests that this beta-blocker might be best
administered twice daily rather than once daily when used
for the purposes of rate control in atrial fibrillation. Thus,
the overall effects of a longer-acting beta-blocker such as
nadolol or timolol on the pattern of the circadian rhythmic-
ity of VR control in atrial fibrillation might differ.
Potential significance of adequate ventricular rate control in
atrial fibrillation. In recent years, a number of lines of
evidence have suggested that sustained elevated heart rate
due to cardiac arrhythmias may lead to tachycardia-induced
cardiomyopathy that may be reversible (4). For example,
incessant supraventricular tachycardia has the potential to
induce striking but reversible reductions in LVEF in pa-
tients without cardiac disease (32). Similarly, uncontrolled
ventricular response in patients with atrial flutter and
fibrillation may induce heart failure which resolves either
with AV nodal ablation and ventricular pacing at slower rate
(33) or simply by control of the ventricular response in atrial
fibrillation by rate-lowering drugs. For example, Grogan et
al. (4) have shown that congestive heart failure with mark-
edly depressed LVEF can follow in the wake of uncon-
trolled VR in atrial fibrillation. In their cases, there was a
marked and relatively rapid improvement in heart failure,
LVEF and exercise capacity when VR was slowed by AV
nodal blocking drugs. Thus, an adequate rate control may
not only relieve symptoms in atrial fibrillation but it may
confer other benefits.
The results of the current study draw attention to a
number of clinically significant issues. For example, what
might constitute an “adequate” VR control in all patients
with atrial fibrillation remains undefined (25). It is not
known whether indices of adequate control should now
include patterns of change in the circadian rhythmicity of
VR, mean heart rate from 24-h Holter recordings or a
defined reduction in the peak heart rate during a standard-
ized exercise test. The results of this study show that
combined regimens of pharmacologic agents can be devel-
oped to test the possibility that continuous and sustained
control of VR over 24 h might lead to the correspondingly
sustained improvement in ventricular function and exercise
capacity along with relief of symptoms.
Study limitations. This study was neither blinded nor
placebo-controlled. Because our intention was not to dem-
onstrate the ability of various drugs to control VR but rather
to compare differences in action and efficacy, the nonblinded
approach may not be a serious limitation. Although the
number of patients studied was relatively small, using the
same cohort of patients for drug regimen comparisons
provided statistical validity for the study. However, no
strong conclusions can be drawn regarding the potency of
different regimens used in this study on exercise capacity.
Further studies of a blinded nature may be of value in
determining the precise effects on exercise capacity relative
to the degree of control of ventricular response in patients
with atrial fibrillation. However, the fact that the data
obtained revealed significant and consistent changes with
respect to other major parameters such as the degrees of
control of the ventricular response during exercise as well as
during daily activities attests to the validity and clinical
relevance of the data from this open-label study.
Conclusions. Digoxin continues to be the first-line therapy
for the control of VR in most patients with CAF, but the data
presented here indicate that, of all the regimens tested in the
same cohort of patients, it was one of the least effective agents
both during ordinary daily activities and during treadmill
exercise. During exercise, diltiazem, a calcium channel-blocker
with noncompetitive antiadrenergic property, significantly at-
tenuated the exercise-induced increases in VR against the
background of digoxin therapy. The combination of the
inhibitory effects of digoxin and diltiazem on the AV node
seemed to be synergistic, but the regimen was significantly less
potent than a similar combination regimen of atenolol and
digoxin. The mean VR over the 24 h was lower on digoxin 1
atenolol than those on digoxin, diltiazem or digoxin 1 dilti-
azem, reflecting the markedly synergistic effect on the AV node
of the vagomimetic actions of the cardiac glycoside and of the
beta-blocking actions of atenolol. The data provide a rational
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basis for the choice of a pharmacologic regimen for rate control
in atrial fibrillation and an approach for defining the signifi-
cance of various regimens for preventing the deterioration of
ventricular and left atrial function.
Reprint requests and correspondence: Dr. Bramah N. Singh,
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